Randomized trials have shown that beta-blockers (BBs) reduce mortality in chronic heart failure (HF). Less data are available on the role of BBs in patients with acute HF, specifically if BBs should be continued or temporarily withdrawn. The aim of this study was to evaluate the role of BBs on in-hospital outcomes of patients admitted for worsening HF in a Cardiology setting.
Introduction
Chronic heart failure (HF) is a clinical syndrome associated with high mortality rates. 1 Over the last 20 years, recognition of the complex pathophysiological mechanisms, involving the reninangiotensin aldosterone system and sympathetic network activity, has clarified our understanding of the development and progression of HF. 2 As a consequence, the pharmacological treatment of HF has improved with the utilization of new drugs, which has been shown to significantly reduce mortality, specifically angiotensin-converting enzyme (ACE) inhibitors, 3, 4 angiotensin receptor blockers, 5, 6 beta-blockers (BBs), and aldosterone † The complete list of the Italian Survey on Acute Heart Failure Investigators has been already published as Appendix of ref 14. antagonists. 7 Several randomized, placebo-controlled clinical trials have clearly demonstrated the efficacy of BBs in reducing mortality in patients with mild-to-moderate HF, 8, 9 severe HF, 10 and in the elderly. 11 At present, BBs represent the mainstay of HF treatment and current guidelines strongly recommend their use 'for all stable patients with current or prior symptoms of HF and reduced left ventricular ejection fraction (EF), unless contraindicated'. 12 Conversely, no clear evidence is available on the use of BBs in unstable patients with HF, and physicians face the daily 'dilemma' of whether to suspend or continue this class of drugs during de novo acute HF or worsening of chronic HF. The European Society of Cardiology guidelines on the diagnosis and treatment of acute HF 13 recommend their early use after an acute episode (usually after 4 days) and suggest that patients on BBs admitted to hospital due to worsening HF should be continued on this therapy unless inotropic support is required. This caution on the prescription of BBs during unstable HF is related to the negative inotropic effect of these drugs, but at present there are no randomized clinical trials or observational studies, indicating that their use significantly increases mortality or morbidity.
On this basis, we evaluated the role of BB therapy on in-hospital outcomes in a real world setting of patients admitted to Cardiology units with a diagnosis of worsening of HF enrolled in the Italian Survey on Acute Heart Failure. 14 
Methods

Study design, collected data, and definitions
Data for the present analysis were obtained from the database of the Italian Survey on Acute Heart Failure, 14 which was designed by a Committee of the Italian Association of Hospital Cardiologists (ANMCO, Florence, Italy) in 2003. Two hundred and six Cardiology Centres agreed to participate in the study. The coexistence of symptoms of worsening HF and objective evidence of cardiac dysfunction was essential, and the need for intravenous drug infusion was a further requirement for patient enrolment. Demographic, clinical, measured and biohumoral variables, and details of treatment were recorded for each patient on entry. The local Institutional Review Boards at each participating centre approved the conduct of the study, and each patient signed a consent form to participate and for the management of their individual data. All patient data were anonymized before being transferred to the Coordinating Centre. All patients were followed-up according to the routine clinical practice of each participating centre. Cardiologists at the participating centre were responsible for confirming the diagnosis of HF and for defining the aetiology of HF and the New York Heart Association (NYHA) class. Left ventricular EF was calculated from four-chamber apical echocardiographic view. Ventricular tachycardia was defined as an episode of tachycardia with widened QRS that lasted longer than 3 beats, with a heart rate of .100 b.p.m. Renal dysfunction was diagnosed when serum creatinine was .2.5 mg/dL. Data on pharmacological treatment were collected at admission, during hospitalization, and at discharge.
Data on in-hospital mortality and major clinical adverse events were collected for each patient. For the purpose of this study, the primary outcome was the association between BB use and in-hospital death for any cause. As secondary outcomes, we considered the occurrence of atrial fibrillation, ventricular malignant arrhythmias (ventricular tachycardia or ventricular fibrillation), syncope, acute coronary syndrome, or stroke. The total length of hospitalization and the number of days spent in the intensive care unit (ICU) were also registered.
Study population
During a period of 3 months between 1 March and 31 May 2003, a total of 2807 consecutive patients admitted to a cardiology ward for acute HF were enrolled in the survey. Of these, 1572 patients presenting with worsening HF are included in this analysis. According to current guideline indications, these subjects should be treated with BB unless they have absolute contraindications or intolerance. We stratified the study cohort into four groups according to treatment with a BB at home (patients having received a BB for at least 7 days before admission) and during hospitalization. Group A (no/no) comprised patients who were never on BB therapy (either at home or during in-hospital stay). Patients included in group B (no/yes) started BB treatment during hospitalization. Patients on chronic BB therapy, in whom BBs were discontinued during hospitalization, were assigned to group C (yes/no). Those patients who were on chronic therapy with a BB and continued treatment during hospitalization were included in group D (yes/yes).
Statistical analyses
Continuous variables are reported as mean + standard deviation and compared using the Kruskal -Wallis test, whereas categorical variables are presented as percentages and compared using x 2 test. Univariate associations between baseline characteristics, main diagnostic procedures, pharmacological/non-pharmacological treatment, in-hospital mortality, and BB therapy (before and during hospitalization) were tested. Age, gender, clinical profile at presentation, and all the variables significantly associated using the unadjusted analysis with all-cause in-hospital mortality were included in a logistic regression model, in order to identify the independent predictors of all-cause in-hospital mortality.
Taking group D as the reference group, three dummy variables were included in the model, in order to estimate the odds ratio (OR) of in-hospital mortality for groups A, B, and C vs. group D. For all continuous variables included in the model, ORs were calculated in terms of 10 unit increments.
A P-value ,0.05 was considered statistically significant. Analyses were performed with SAS system software (SAS Institute Inc., Cary, NC, USA, version 8.2) and the R development core team (R foundation for statistical computing, Vienna) (Zelig Package 16 June 2008, Version 3.3-1).
Results
Baseline characteristics
The study population comprised 1572 patients; 811 of whom never started BB therapy (group A no/no, 51.6%), whereas 258 patients started BBs during hospitalization (group B no/yes, 16.4%); in 141 patients, BB therapy was discontinued during hospitalization (group C yes/no, 9.1%) and 362 patients continued BB therapy during hospitalization (group D yes/yes, 23.0%). Demographic, clinical, echocardiographic, and biohumoral variables measured on admission to the cardiology ward are reported in Table 1 . The mean age of the study population was 72 + 11 years, whereas it was 73 + 10 years in groups A, B, and C and 70 + 11 years in group D. Nearly half of the patients were aged 75 years or more (44.1%), with a higher prevalence in groups A and B (P ¼ 0.004). Patients in groups C and D were more likely to have had a previous myocardial infarction (P , 0.0001) and to have been treated with percutaneous coronary intervention (,0.0001), coronary by-pass (,0.0001) as well as permanent pacemaker (,0.0001) or an implantable cardiac defibrillator (,0.0001). These patients were also those who had a higher hospitalization rate for HF in the previous year (P ¼ 0.0008). A history of chronic obstructive pulmonary disease was present in a higher proportion of patients in group A (P , 0.0001).
Clinical presentation
All patients were admitted to the cardiology unit with one of the following diagnoses: cardiogenic shock (6.9%), acute pulmonary oedema (46.0%), or worsening NYHA class necessitating hospitalization (47.1%). Patients in groups B and C more frequently presented with cardiogenic shock or acute pulmonary oedema (P ¼ 0.006) and had a higher prevalence of pulmonary rales (P ¼ 0.033) at entry. On admission, groups A and B had a higher prevalence of subjects with a heart rate .100 b.p.m.
(P ¼ 0.0012) and more frequently presented with atrial fibrillation (P , 0.0001) compared with the other groups. Severe systolic hypotension, defined as systolic blood pressure ,90 mmHg, and anaemia were more frequently observed in patients in groups A and C (P ¼ 0.025 and 0.008, respectively). A serum creatinine .2.5 mg/dL was measured in 9.6% of the study population, with a higher prevalence in groups A, C, and D (P ¼ 0.019). Hyponatraemia (e.g. serum sodium ,132 mEq/L) was more frequent in patients in groups A and C (P ¼ 0.024).
A wide QRS (120 ms) at the ECG on admission was detected in 36.1% of the study population (73.8% with left bundle branch block) and was more frequent in patients from groups C and D (P ¼ 0.0002). These patients had a more severe reduction in left ventricular EF (EF ,30%) measured during hospitalization with transthoracic echocardiography (43.7 and 45.7% vs. 32.1 and 36.4% of groups A and B; P , 0.0001). No statistically significant differences were found in the other clinical variables.
Pharmacological treatments
Treatments on admission and during hospitalization are shown in Table 2 . Significant differences were found in the use of several drug therapies across the four groups at admission and during hospitalization. At admission, a higher percentage of patients in groups C and D were treated with ACE inhibitors or angiotensin receptor blockers, aldosterone blockers, diuretics, statins, nitrates, and antiplatelet agents (all P , 0.0001). Nearly one-third (28.8%) of the patients required inotropic support during hospitalization, with a higher percentage in group C (P , 0.0001).
Clinical events and length of in-hospital stay
As shown in Table 3 , with the exception of the proportion of patients with atrial fibrillation (38.4% in the total population) which was higher in group A (44.0 vs. 38.4, 28.4, and 29.8% in groups B, C, and D; P , 0.0001), there were no significant differences between the four groups for other clinical events such as incidence of ventricular arrhythmias, acute coronary syndromes, stroke, and syncope. No differences between the four groups were observed in the total length of hospitalization (group A 12.5 + 11.0 days, group B 11.1 + 7.6 days, group C 13.9 + 19.5 days, group D 11.1 + 7.5 days; P ¼ 0.51) or in the time spent in ICU (group A 4.9 + 4.5 days, group B 4.9 + 4.4 days, group C 4.7 + 3.9 days, group D 4.4 + 3.2 days; P ¼ 0.93).
All-cause mortality
Of the 1572 patients with worsening HF enrolled in the study, 112 (7.1%) died during hospitalization. As shown in Figure 1 , overall in-hospital mortality in the study population was significantly higher in patients from groups A and C, who were either never on prescribed BB therapy (82/811; 10.1%) or discontinued BB therapy during hospitalization (17/141; 12.1%), respectively. Cardiovascular death accounted for nearly 96% of total deaths, and no difference was observed across the four groups. Analysing the different cardiovascular causes of death, we found that death caused by worsening HF was the most frequent (75/107 patients, 70.1%). Interestingly, 11 of the 13 fatal arrhythmic events (84.6%) occurred in patients from group A.
The association between BB use and lower mortality rate, demonstrated with the univariate analysis, was confirmed by the analysis adjusted for clinical, haemodynamic, and therapeutic variables (Figure 2) . Considering group D as the reference group, we observed a higher in-hospital mortality rate in groups A and C [OR 3.28, 95% confidence interval (CI) 1.47-7.32, P ¼ 0.004, and OR 4.20, 95% CI 1.59-11.10, P ¼ 0.004, respectively], whereas no difference was found between groups B and D (OR 0.34, 95% CI 0.07-1.78, P ¼ 0.20).
Among the other variables for which the model was adjusted, age (as continuous), previous revascularization, systolic blood pressure (as continuous), haemoglobin at entry (as continuous), and inotropes during hospital stay were independent predictors of in-hospital mortality.
The results of the multivariable analysis are reported in Table 4 .
Discussion
Our study was designed to verify, in a 'real world' setting, the prognostic role of BBs in the acute phase of worsening chronic HF, with the aim of supporting physicians' decision-making because of the large lack of data on this topic. Major concerns about the utilization of BBs during the unstable phase of HF are related to the potential adverse consequences of their short-term negative inotropic effects. 15 However, it has been demonstrated that BBs are well tolerated in patients with severe chronic HF 16 and that the magnitude of benefit on mortality and morbidity is similar, regardless of the severity of chronic HF. 17 A recently published analysis of the Organized
Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure trial (OPTIMIZE HF) demonstrated that the use of carvedilol at discharge was associated with a significant reduction in mortality risk at 60-90 days compared with no pre-discharge BB, improving long-term adherence to recommendations of practical guidelines. 18 In a recent analysis of the COMET trial, Metra et al. 19 demonstrated that after hospitalization for an episode of worsening HF, maintenance of BB therapy (same dosage at the visit previous and subsequent to hospitalization) was associated with better medium-/ long-term outcome compared with withdrawal or dose reduction after discharge. The results of these studies seem to suggest that BBs might also be important after an episode of acute worsening HF, but these findings do not strongly support this hypothesis during the acute phase because the methodological analysis provides no information on the use of BBs during hospitalization and their effect on in-hospital mortality. Our data seem to support the prognostic role of BBs in the acute setting, as previously observed in the chronic phase. During worsening chronic HF, maintenance of home therapy with BB or their introduction during hospitalization is not associated with an enhancement of in-hospital clinical adverse events. In fact, atrial fibrillation was the only event that occurred with a statistically different frequency in the four groups, and it was more often present in patients from groups A (never on BB) and B (started BB during hospitalization) who probably lacked the wellknown protective effect of these drugs on arrhythmia.
Signs and symptoms of worsening HF are common reasons for discontinuation of BB therapy in clinical practice. 20 Enduring signs and symptoms are probably the strongest determinants of hospital length of stay, and some authors have suggested that early introduction of BB during an acute episode of HF might prolong hospitalization. 21 Contrary to this theory, in our study, BBs did not seem to cause prolongation of hospitalization, and no differences in total length of stay or in days spent in ICU across the four groups were found. The positive effect of BBs in terms of mortality reduction, firmly established in patients with chronic HF, also seems to be confirmed in the acute phase. The in-hospital mortality of our study population was 7.1%, a mortality rate comparable with that previously observed in similar registries. 22 Using the univariable analysis, compared with the other two groups, a higher risk of mortality was observed in group A (patients who were never on a BB) and particularly in group C (patients who discontinued BB treatment during hospitalization for chronic HF). These results were confirmed at the multivariable analysis, after adjustment for possible available confounding demographic and clinical variables and for home and in-hospital treatment, where again we observed a strong association between in-hospital mortality and non-use or withdrawal of BB. Our results are in agreement with those of a retrospective analysis of the Outcomes of the Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). In this study, among 212 patients treated with BBs at the time of admission for worsening HF, 47 patients who permanently discontinued BBs had a less favourable outcome. 23 We should not forget that in this setting the choice of inotropic drugs might be critical, because the positive cardiovascular haemodynamic effects of this therapy can be modified according to the type of BBs used. In fact, carvedilol and metoprolol do not impair the improvement in systemic and pulmonary indexes registered during enoximone infusion; however, carvedilol and, to a lesser extent, metoprolol treatment may significantly inhibit the favourable haemodynamic response to dobutamine. 24 It is not easy to give a pathophysiological explanation for these findings. Analysing the causes of cardiovascular death (nearly 96% of allcause mortality), we can see that, in the vast majority of cases, death was caused directly by pump failure, whereas fatal arrhythmic events were not particularly frequent. In advanced HF, this high prevalence of death due to pump failure compared with sudden death, which is known to be predominant in the early stages of disease, is well recognized in the literature. 25 As a consequence, the observed positive association of BB use with lower mortality can be only partly explained by the prevention of malignant ventricular arrhythmias, whereas protection against acute negative mechanical remodelling, which may initiate the development of fatal pump failure, could be hypothesized.
Study limitations
Some limitations in our study must be acknowledged. Our data derive from a survey in which therapy was registered as home therapy (at least 7 days before hospitalization), therapy at admission, therapy during hospitalization, and therapy at discharge; no data were collected on the dosage or on the type of BBs used at home and during hospitalization. For the same reason, we lack information concerning when BB therapy was started or withdrawn during hospitalization. In the multivariable analysis, we adjusted for variables that are markers for disease severity, but this adjustment may be incomplete; for example, in-hospital mortality rate in the four different groups was obtained from the vital status of patients at discharge and no data were collected on the timing of death during hospitalization. For this reason, some of the patients might have died soon after hospital admission without having had the chance of starting a BB. In any case, findings on treatment effects derived from observational studies, even when appropriately statistically adjusted for possible confounders, must be regarded with caution and considered just as 'hypothesisgenerating' for specific randomized trials.
Conclusions
This study provides clinical evidence to support the hypothesis of maintaining BB therapy during hospitalization for decompensated HF. However, adequately powered prospective randomized clinical trials are required to confirm these findings before it can be concluded that BBs should be continued in this setting and that their withdrawal might be harmful.
